Visit In the Pipeline

Eat It, Breath It, Soak in It?

Posted on January 18, 2008

After Pfizer s Exubera inhaled-insulin product died so horribly in the market last year, the other companies working in the same space had to be worried. Lilly and Alkermes have had a long-running program, as has a smaller company called Mannkind. But recently, another contender, Novo Nordisk, has announced that they and partner Aradigm have decided to cut their losses. The In Vivo Blog has an excellent roundup.According to Novo s CEO, they (like Pfizer) were focusing on prandial insulin because that was basically the only thing they could get to work through inhalation. Now that they ve...

Original article link


insulin , liver , lung , lungs , proteins , running , skin